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Abstract
Intraperitoneal metastases commonly recur after sur-
gery because small tumor foci escape detection within
the complex anatomy of the peritoneal cavity and
mesentery. Accurate localization of peritoneal implants
during surgery could improve the resection of ovarian
cancer and other malignancies, but few practical tech-
niques to enhance detectability are currently available.
Here, we describe a targetedmolecular imagingmethod
that employs fluorescently labeled avidin to detect
submillimeter peritoneal implants of ovarian cancer in
mice. After binding to surface lectins on the tumor,
fluorescein-conjugatedavidinenabled thespectral fluo-
rescence imaging of disseminated peritoneal implants.
High spatial resolution and high tumor-to-background
ratio allowed the visualization of implants as small as
0.3 mm (with 100% sensitivity and specificity; n = 150)
and the identification of even smaller lesions ex vivo.
These results suggest that targeted molecular imaging
with a fluorescence-labeled lectin–ligand system is a
promising technique for the detection of disseminated
submillimeter foci of cancer.
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Introduction
Malignant peritoneal implantation is an often fatal complica-
tion of cancers originating from abdominal organs, such as
the ovary, stomach, colon, and pancreas. Surgical debulking
is associated with prolonged survival, but recurrences are
common [1,2]. The completeness of the initial resection
influences clinical outcome, but is often limited by the sur-
geon’s ability to localize cancers within the complex anat-
omy of the peritoneal cavity. Improved methods of detecting
small lesions could lead to more effective cytoreduction,
which could also improve response to adjuvant systemic and
intraperitoneal chemotherapy [1,2]. Detection methods
based on radiolabeled probes and gamma scintigraphy
have been hampered by poor image resolution [3,4], whereas
nontargeted optically based imaging methods have proven
nonspecific or toxic and must overcome signals arising from
normal autofluorescence [5].
Recently, the number of high-quantum-yield fluorophores
available for in vivo optical imaging has increased dramatically
[6]. However, simply applying these fluorophores to the peri-
toneal surface is unsatisfactory because differential enhance-
ment between the tumor and the normal background is minimal
[7]. To reliably detect submillimeter tumor foci in vivo, endos-
copy or surgery requires targeted fluorescence probes that yield
high signal-to-background ratios. This can be achieved by
effectively targeting the tumor with high-quantum-yield fluoro-
phores, while simultaneously eliminating the same fluorophore
from the background. Green fluorophores provide sufficiently
different spectra from autofluorescence that they can usually be
discriminated from the background spectra, which peak in the
visible red spectrum. Ordinarily, green fluorophores are not
ideal for in vivo imaging because of their short penetration
within tissues; however, when only the surface is being imaged,
green fluorophores are completely satisfactory. Fluorescein, a
bright green fluorescence dye, is currently used clinically to
perform retinal angiography [8]. Based on its long human ex-
perience and its low toxicity, fluorescein was selected to image
peritoneal implants using a targeting strategy.
Lectins are expressed on the surface of many cancer cells
and are, therefore, good candidates for targeted imaging and
therapy probes [3,4,9–11]. Lectins are proteins that specifically
bind to carbohydrate groups on glycoproteins and glycolipids
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[3,4,9–11]. Glycoproteins such as avidin (a 68-kDa tetra-
meric glycoprotein) and galactosyl serum albumin bind avidly
to lectins [3,4,10,12]. Because avidin is positively charged, it
readily binds to lectin or other lectin-like negatively charged
molecules at physiological pH. Bound avidin is subsequently
internalized into cancer cells. In addition, unbound lectin-
binding proteins are rapidly absorbed through the peritoneal
membrane, enter the circulation, and are quickly trapped by
the liver. Thus, fluorescein–avidin conjugates that bind to
lectin are quickly internalized, whereas unbound fluorescein–
avidin conjugates are rapidly taken up by the liver, away from
the peritoneal membrane. Thus, this agent is capable of
very high target-to-background ratios.
Herein, we study the use of intraperitoneally administered
fluorescein-conjugated avidin (Avidin–FITC) in a mouse
model of ovarian cancer to determine the feasibility of using
this strategy for detecting microfoci of peritoneal metastases.
Materials and Methods
Chemicals
Avidin–FITC and fluorescein-conjugated deglycosylated
avidin (NeutrAvidin–FITC) were purchased from Pierce
(Rockford, IL). Pure FITC compound (fluorescein) was pur-
chased from Molecular Probes (Eugene, OR).
Cell Line and Cell Culture
An established ovarian cancer cell line, SHIN3 [13], was
used for generating intraperitoneal disseminated tumors. Cell
lines were grown in RPMI 1640 medium (Gibco, Gaithers-
burg, MD) containing 10% fetal bovine serum (Gibco), 0.03%
L-glutamine at 37jC, 100 U/ml penicillin, and 100 mg/ml
streptomycin in 5% CO2.
Tumor Model
All procedures were carried out in compliance with the
Guide for the Care and Use of Laboratory Animal Resources
(1996), the National Research Council, and were approved
by the National Cancer Institute Animal Care and Use Com-
mittee. Intraperitoneal tumor xenografts were established
by an intraperitoneal injection of 2  106 cells suspended in
200 ml of phosphate-buffered saline (PBS) in female nude
mice (National Cancer Institute Animal Production Facility,
Frederick, MD). Experiments with tumor-bearing mice were
performed at 12 to 16 days after injection of the cells
when only a few visible tumors and numerous microfoci are
typically present.
In Vivo Fluorescence Imaging
After the intraperitoneal injection of 50 mg of Avidin–FITC
diluted in 300 ml of PBS into tumor-bearing mice, the mice
were anesthetized by gas mixtures of 1.5% isoflurane and air
and then sacrificed (n = 3 in each group). The abdominal walls
were removed, and spectral fluorescence images were
obtained using the Maestro In Vivo Imaging System (CRI,
Inc., Woburn, MA). Whole abdominal images and close-up
peritoneal membrane images were obtained. A bandpass
filter from 445 to 490 nm and a longpass filter > 515 nm
were used for emission and excitation light, respectively.
Tunable filter was automatically stepped in 10-nm increments
from 500 to 800 nm, whereas the camera captured images
at each wavelength interval with constant exposure. Spec-
tral unmixing algorithms were applied to create unmixed
images of fluorescein and autofluorescence. Three mice
were studied in each group, and all images were analyzed
using the Maestro software provided.
Studies of Collected Tumor Nodules and Major Organs
Four hours after injection of Avidin–FITC, disseminated
tumor nodules were excised and imaged along with other
major organs: liver, spleen, stomach, intestine, kidneys,
lungs, and heart. Using spectral unmixing algorithms, FITC
and autofluorescence spectra were obtained from the tumor
and the peritoneum. Pathological examination was per-
formed using standard hematoxylin and eosin (H&E) staining.
Comparison Studies of Avidin–FITC and NeutrAvidin–FITC
or FITC
Four hours after the intraperitoneal injection of 50 mg of
Avidin–FITC, 50 mg of NeutrAvidin–FITC, 65 mg of Neutr-
Avidin–FITC (the same FITC dose as 50 mg of Avidin–FITC),
or 0.73 mg of FITC (the same FITC dose as 50 mg of Avidin–
FITC) compound diluted in 300 ml of PBS was injected into
tumor-bearing mice. The peritoneal membrane was re-
sected, and conventional fluorescence imaging was per-
formed using a bandpass filter from 445 to 490 nm for
excitation light and using a longpass filter > 515 nm for
emission light. The exposure time was 500 milliseconds.
Then, fluorescence signals from tumor foci were visually
compared between Avidin–FITC, NeutrAvidin–FITC, and
unconjugated FITC.
Detection Capability of Disseminated Cancer Microfoci
A nonfluorescent optically black plate was placed under
the peritoneal membrane of tumor-bearing mice (n = 3), a
ruler was placed on the specimen adjacent to the tumor
microfoci, and in vivo fluorescence imaging was performed
4 hours after the intraperitoneal injection of 50 mg of Avidin–
FITC diluted in 300 ml of PBS. The detection size limit for
tumor microfoci was determined visually using an unmixed
composite image.
Ex Vivo Validation Study of Fluorescence Signal
in Submillimeter Tumor Nodules
Ex vivo fluorescence images of the peritoneum were
performed 4 hours after the intraperitoneal injection of
50 mg of Avidin–FITC diluted in 300 ml of PBS, using a
high-resolution imaging system (FLA-5100; Fujifilm Medical
Systems USA, Inc., Stanford, CT). Small (millimeter to sub-
millimeter) peritoneal implants were excised and imaged.
An internal laser of 473 nm, used for excitation with a long-
pass filter of > 530 nm (530DF20 for FITC), was employed for
light emission. Both lateral and longitudinal spatial re-
solutions (pixel size) were 25 mm. Fluorescence intensity
distributions within small nodules were evaluated visually.
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To validate the sensitivity and specificity of the Avidin–
FITC method, 50 to 150 lesions/mouse were randomly
resected using conventional optical methods. It was not
possible to reliably locate lesions < 0.3 mm in diameter under
white light conditions; thus, this was the de facto lower size
limit for this study. Lesions up to 5 mm constituted the upper
size limit. Each lesion was examined for green fluorescence,
using the Maestro system. Lesions were subsequently
resected, fixed with 10% formalin, stained with H&E, and
examined for the presence of tumor cells in each lesion.
Fluorescence Microscopy
To determine the location of Avidin–FITC, fluorescence
microscopy was performed ex vivo and in vitro. After the de-
tection of highly fluorescent submillimeter implants on the
4-hour in vivo fluorescence image, implants were extracted
from the peritoneal membrane and smeared on a slide glass
for fluorescence microscopy. For in vitro fluorescence mi-
croscopy, SHIN3 cells (5 105) were plated on a coverglass-
bottom culture well and incubated for 16 hours. Avidin–FITC
was added to the medium (333 ng/ml), and the cells were
incubated for another 4 hours. Cells were washed once with
PBS. Fluorescence microscopy was performed using an
Olympus BX51microscope (Olympus America, Inc., Melville,
NY) equipped with the following filters: excitation wave-
length of 470 to 490 nm and emission wavelength of 515 nm
(longpass). Transmitted light differential interference contrast
(DIC) images were also acquired.
Results
Determining Optimal Imaging Time with Avidin–FITC
To determine the optimal timing for imaging, dynamic
in vivo spectral fluorescence images (Figure W1) were ob-
tained 1, 2, 4, and 8 hours after the intraperitoneal injec-
tion of 50 mg of Avidin–FITC. The fluorescence arising from
tumor foci was observed as early as 1 hour after the intra-
peritoneal injection of Avidin–FITC (Figure 1A); however,
the background signal at this time was still high due to in-
complete clearance of Avidin–FITC in the peritoneal fluid.
At 2 hours after Avidin–FITC injection, the tumor signal
was higher, but the background signal was also still high
(Figure 1B). However, by 4 hours after Avidin–FITC injection,
tumor foci were more clearly depicted due to the clear-
ance of the unbound reagent from the peritoneal cavity
Figure 1. In vivo spectral fluorescence images of tumor-bearing mice. Composite images (red: autofluorescence; green: FITC fluorescence) were obtained 1, 2, 4,
and 8 hours after injection of 50 g of Avidin –FITC (A, 1 hour; B, 2 hours; C, 4 hours; D, 8 hours). (A and B) High fluorescence intensity was observed in tumor foci,
but the background signal was still high within 2 hours postinjection. (C) Aggregated tumor foci (white arrowheads) and a small tumor nodule (white arrow)
measuring < 5 mm are clearly shown 4 hours postinjection. (D) At 8 hours postinjection, the fluorescence from tumor foci (blue arrowheads) became very weak and
almost unidentifiable. Imaging is optimized at approximately 4 hours postinjection.
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(Figure 1C). At 8 hours postinjection, both tumor and back-
ground signals decreased, and tumor foci were almost un-
detectable as clearance occurred in the tumor (Figure 1D).
Based on these results, it was determined that the optimal
timing for imaging was approximately 4 hours postinjection
of 50 mg of Avidin–FITC.
Sensitivity, Specificity, and Detection Limit
To confirm that Avidin–FITC was bound to cancer cells
and not to the normal peritoneum, 50 to 150 tumor nodules
ranging in size from 0.3 to 5 mm were harvested and imaged
along with other organs. A rim of normal nonfluorescing
tissues was also resected and evaluated. Using spectral un-
mixing, the fluorescence signal from the tumor nodules
was clearly distinguished from the autofluorescence of the
gastrointestinal tract and of the other organs (Figure 2A).
All fluorescing tumor nodules were pathologically confirmed
as SHIN3 ovarian cancers, using standard H&E staining
(Figure 2B). No nonfluorescing tissue proved to harbor
cancer. The lesions of the peritoneal membrane that are as
small as 0.3 mm in diameter were clearly depicted in vivo
(Figure 2C). Among lesions z 0.3 mm in diameter (n = 150),
the sensitivity of the spectral unmixed image obtained 4 hours
postinjection with 50 mg of Avidin–FITC was 100% and the
specificity was 100%.
To establish the detection limits of this technique, fluores-
cence microscopy was performed ex vivo. High-resolution
fluorescence-scanned images of small peritoneal nodules
demonstrated high fluorescence signals arising within 100 mm
of the free surface of the nodule, suggesting that Avidin–
FITC was bound to or absorbed only by superficial cancer
cells within the implant and was not distributed throughout
the tumors (Figure 2D). Thus, Avidin–FITC could homoge-
neously accumulate only in tumor implants up to a diameter
of 100 mm (Figure W2). Numerous lesions smaller than
0.3 mm were detected on the peritoneal membrane by spec-
tral fluorescence imaging with a minimal detectable diameter
of approximately 0.1 mm. Microscopically, every fluorescent
nodule contained clusters of cancers cells when stained with
H&E, and there were no false-positive results, although it
was impractical to survey the entire peritoneal surface at
microscopic resolution.
Mechanism of Avidin–FITC Binding and Interaction
To test whether Avidin–FITC bound specifically to cancer
foci by the interaction of glycosylation on avidin and lectin, we
compared the fluorescence intensities of Avidin–FITC and
NeutrAvidin–FITC or unconjugated pure FITC (Figure 3).
Fluorescence images with 50 mg of Avidin–FITC clearly
depicted small cancer foci on the peritoneal membrane
(Figure 3D; Figure W3), whereas images with 65 mg of Neutr-
Avidin–FITC (the weight difference is determined to achieve
an equivalent number of FITC molecules) (Figure 3A) or
0.73 mg of unconjugated FITC (the same FITC dose as
50 mg of Avidin–FITC) (Figure 3B) showed minimal fluores-
cence from tumor foci under the same conditions. We also
confirmed that there was insignificant binding of Avidin–
FITC to the extracted normal peritoneal tissue (Figure 3C;
Figure W2). These results indicate that Avidin–FITC specifi-
cally accumulates in SHIN3 peritoneal cancer implants and
Figure 2. Sensitivity, specificity, and detection limit. (A) Ex vivo composite image of tumor and organ. Four hours postinjection, the image clearly distinguished the
Avidin–FITC fluorescence of the tumor from the autofluorescence of the gastrointestinal tracts and of other organs (red: autofluorescence; green: FITC
fluorescence). The arrowhead indicates the gallbladder. T, tumor nodules; Li, liver; Sp, spleen; St, stomach; I, intestine; K, kidneys; Lu, lung; H, heart. (B)
Microscopy of extracted peritoneal implants. SHIN3 cancer implants (arrows) were located on the free surface of the peritoneal cavity (original magnification, 200;
H&E stain). (C) In vivo composite image of the peritoneum (red: autofluorescence; green: FITC fluorescence) obtained 4 hours postinjection of 50 g of Avidin–
FITC clearly depicted submillimeter peritoneally disseminated implants of ovarian cancer. Cancer implants as small as 0.3 mm are clearly depicted. The scale on
the ruler represents 1 mm. (D) High-resolution fluorescence image of peritoneal implants. High fluorescence signal can be seen to a depth of approximately 100 m
along the peritoneal surface of the tumor (arrowheads).
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that the mechanism of interaction proceeds by the binding
of glycosylation on avidin to lectin [14].
Detection of Intracellular Location of Avidin–FITC
To determine the cellular location of Avidin–FITC, fluo-
rescencemicroscopy was performed 4 hours after incubation
with Avidin–FITC. The fluorescence microscopy of extracted
peritoneal submillimeter implants smeared on a slide glass
demonstrated clustering punctate fluorescent dots within the
cytoplasm of cells (Figure 4A). To confirm that these were
located within SHIN3 cancer cells, in vitro fluorescence
microscopy and DIC were performed. Fluorescence micros-
copy of cultured SHIN3 cells more clearly showed a large
number of fluorescent dots within the cytoplasm (Figure 4, B
and C), indicating that Avidin–FITC was internalized and
located within the endoplasmic vesicles, as previously pre-
dicted using a radioisotope method [3,4,10].
Discussion
Avidin–FITC can be used to improve the detection of micro-
foci of disseminated peritoneal metastasis because it
produces high target-to-background fluorescence ratios.
Avidin–FITC appears to internalize once bound to cancer
cells, whereas unboundAvidin–FITC is cleared rapidly by the
liver. The accumulation of Avidin–FITC within SHIN3 peri-
toneal tumor implants is consistent with a previous study
using 111In-labeled avidin [3]. However, the image quality and
spatial resolution of optical imaging are superior to those of
the radionuclide technique [3,4]. This is also achieved with-
out exposure to ionizing radiation. Moreover, optical imaging
is substantially more practical than radionuclide methods as
a means of guiding surgical resection. This technique is es-
pecially well adapted to laparoscopic surgery, which already
relies on optical cameras and could easily be adapted to
fluorescence imaging. Furthermore, with optimized fluoro-
phores and cameras, it may be possible to detect lesions
below 100 mm in diameter based on fluorescent microscopy
results (Figure 2D; Figure W2) [15,16]. Because other types
of cancers besides ovarian cancer are capable of internaliz-
ing avidin [3,4,9,10], thismethodmay be applicable to a broad
range of intraperitoneal malignancies.
Fluorescein was chosen as the fluorophore in this study
because it is widely available, it has been extensively tested
Figure 3. Nonspectral fluorescence images of extracted peritoneal membrane with (A, B, D) or without (C) tumor implants. (A) Fluorescence image of
NeutrAvidin –FITC at a dose of 65 g. Sixty-five micrograms of NeutrAvidin –FITC contains the same number of FITC molecules as 50 g of Avidin–FITC.
Implants are invisible. (B) Fluorescence image of unconjugated FITC at a dose of 0.73 g. An amount of 0.73 g of FITC contains the same number of FITC
molecules as 50 g of Avidin –FITC. Implants and vascular structures are barely seen. (C) Fluorescence image of Avidin–FITC at a dose of 50 g in a normal
mouse without tumor. No focal uptake is shown. (D) Fluorescence image of Avidin–FITC at a dose of 50 g. Relatively larger tumor foci (> 1 mm in diameter) are
easily detectable (arrows), whereas smaller foci are barely visible (arrowheads). The ruler represents 1 mm. The exposure time was 500 milliseconds in all images.
Figure 4. In vivo and in vitro fluorescence microscopy. Avidin–FITC similarly
accumulated in SHIN3 cells both in vivo and in vitro. (A) Fluorescence
microscopy of the peritoneal implants 4 hours postinjection with 50 g of
Avidin–FITC demonstrates clusters of punctate fluorescence within the cells
(original magnification, 200). In vitro fluorescence microscopy (B) and DIC
(C) images of SHIN3 cancer cells. After 4 hours of incubation with Avidin–
FITC (333 ng/ml), a large number of fluorescent dots are detected within the
cytoplasm of SHIN3 cells.
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clinically, and it has been found to have minimal toxicity.
Fluorescein, however, is not the ideal fluorophore for in vivo
imaging because of its green emission wavelength and its
susceptibility to photobleaching; however, notwithstanding
these limitations, the agent performed well in this setting.
Other fluorophores that emit light in this spectral region may
be suitable as well. Most intravenously injected optical
probes use fluorophores in the near-infrared range; however,
this is not needed for surface applications such as peri-
toneal implants.
A limitation of Avidin–FITC for human use is the immuno-
genicity of avidin [17]. The avidin molecule may need to be
modified to reduce its immunogenicity before it is considered
in human applications. However, this may be possible be-
cause only the carbohydrate chain of avidin is responsible
for the binding of lectin, whereas the protein core could be
changed from avidin to galactosyl human serum albumin to
minimize immunogenicity and toxicity [4].
It was challenging to determine the minimally detectable
lesion using this method. Using white light optical imaging
of the peritoneum as the ‘‘gold standard,’’ a practical limit of
0.3 mm was found. Lesions z 0.3 mm proved to contain
cancers in all cases. There were no false-negative or false-
positive results among the 150 lesions, leading to 100% sen-
sitivity and specificity at least for lesions z 0.3 mm. It was
common to microscopically detect lesions < 0.3 mm down to
approximately 0.1 mm (approximately 1000-cell clusters);
however, to detect these lesions in vivowould require spectral
imaging devices with a resolution higher than those that
we have access to. Furthermore, it is difficult to physically
measure lesions of this dimension in vivo. As lesions de-
crease in size, fewer cells are stained with fluorophores, so
that the absolute light output from smaller lesions is lower.
Determining a threshold value of light output that is still
consistent with tumor accumulation will require additional
research. It is hoped that newer detectors, cameras, and
fluorophores may enable the detection of tiny clusters con-
taining < 1000 cancer cells.
Ovarian cancer is the fifth leading cause of cancer deaths
among American women [18]. Ovarian cancer causes death
predominantly by direct organ invasion and intraperitoneal
dissemination. Smaller residual tumor volumes after cyto-
reductive surgery are associated with better clinical out-
comes [19,20]. Optically enhanced surgical resection, using
fluorescence cameras in the operating room, may enable
surgeons to eradicate submillimeter cancer foci, which are, at
best, difficult, if not impossible, to see with the naked eye.
Better resections are expected to improve treatment out-
comes by making adjuvant therapies (such as intraperitoneal
chemotherapy, hyperthermia, radioimmunotherapy, or photo-
dynamic therapy) more effective.
In conclusion, Avidin–FITC, a lectin-targeted fluores-
cence imaging technique, improves the visualization of sub-
millimeter foci of peritoneal tumor implants in an ovarian
cancer model. Avidin–FITC binds to the tumor cell surface,
internalizes in the cell, and accumulates, leading to optimal
target 4 hours postinjection. Although extensive clinical ex-
perience exists for fluorescein, avidin is known to be immu-
nogenic; however, it is possible to modify avidin to retain its
binding affinities while reducing its immunogenicity. Thus,
this paradigm of optically targeted fluorescence molecular
imaging is one that could readily be translated to the clinic.
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Figure W1. In vivo spectral images. After spectral unmixed autofluorescence image (A) and spectral unmixed FITC fluorescence image (B) had been obtained, a
composite image (C) was created with Maestro In Vivo Imaging System (red: autofluorescence; green: FITC fluorescence). These images were taken 4 hours after
injection with 50 g of Avidin–FITC (same case as in Figure 1 C).
Figure W2. In vivo fluorescence microscopy and DIC images of the peritoneal micronodule after injection with Avidin –Rhodamine-G. A fluorescence microscope
image (40) of a micronodule (A) on the peritoneal membrane was shown together with the same view taken by DIC (B). Avidin–Rhodamine-G was accumulated
in SHIN3 cells in a micronodule of 100 m diameter, but not in normal peritoneal tissues. The tumor specimen was taken at 4 hours postinjection of 50 g of
Avidin–Rhodamine-G into a mouse bearing peritoneally disseminated SHIN3 ovarian cancer. Tumor cells showed high fluorescence with minimal background
signal from normal peritoneal tissues. In supplemental experiments (Figures W2 and W3), solid fluorescence dyes (Rhodamine-G and BODIPY) were selected to
avoid photobleaching. Fluorescein is prone to photobleaching; therefore, BODIPY or Rhodamine-G was used as alternative. These results show that alternative
fluorophores can use the same avidin system to achieve tumor targeting without some of the disadvantages of fluorescein.
Figure W3. Comparison between Avidin–BODIPY and NeutrAvidin –BODIPY. SHIN3 cells (5  105) were plated on a coverglass-bottom culture well and
incubated for 16 hours. BODIPY-conjugated Avidin (Avidin–BODIPY) and BODIPY-conjugated NeutrAvidin (NeutrAvidin–BODIPY) were added to the medium
(10 g/ml), and the cells were incubated for another 4 hours. Cells were washed once with PBS, and fluorescence microscopy was performed using the following
filters: excitation wavelength of 470 to 490 nm, emission wavelength of 515 nm (longpass), and exposure time of 5 seconds. Fluorescence microscopy showed a
large number of fluorescent dots within the cytoplasm of SHIN3 cells incubated with Avidin–BODIPY, whereas a few fluorescent dots were seen in those incubated
with NeutrAvidin –BODIPY. For direct comparison, flow cytometry was performed 48 hours after incubation with Avidin –BODIPY and NeutrAvidin–BODIPY in the
same concentration (10 g/ml). Then, unstained control (—) and BODIPY-stained (—) profiles are overlaid. A plot overlay of Avidin –BODIPY demonstrated a
significant shift. However, the plot overlay of NeutrAvidin–BODIPY showed a minimal shift of fluorescence intensity.
